Pidilizumab
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].
Product Specifications
CAS Number
1036730-42-3
Product Name Alternative
CT-011; MDV9300
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pidilizumab.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Pidilizumab]
Molecular Weight
(144.626 kDa)
References & Citations
[1]Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15 (1) :69-77.|[2]Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40 (14) :6450-6462.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
DRE723 24 Cases / 72 Cores
Rectum adenocarcinoma (grade 2) tissue array with adjacent normal tissue, including pathology grade, TNM and clinical stage, 24 cases/72 cores
Sign In for Pricing
View Details 
MBS6502102-01 0.1 mL
TASP1, CT (Threonine Aspartase 1, Taspase-1, TASP1, C20orf13) (MaxLight 490)
Sign In for Pricing
View Details MBS6502102-02 5x 0.1 mL
TASP1, CT (Threonine Aspartase 1, Taspase-1, TASP1, C20orf13) (MaxLight 490)
Sign In for Pricing
View Details